Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §2

Semaglutide — pharmacology

Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.

Document identifier
CEI-MN-001/2
Series
Compound monograph
Version
1.1
Published
16 Sep 2023
Last reviewed
16 Aug 2024
Next review
16 Aug 2026
Identifier
10.71829/cei.mono.1
Certainty
High
Cycle
2023 Q3

§2Pharmacology

§2.1Molecular targets

Table 2. Molecular targets recorded for Semaglutide, with the character of the interaction and the potency where the Institute holds it.

TargetInteractionNote
GLP-1 receptor (GLP1R)Full agonistEC₅₀ ≈ 0.1 nM; affinity approximately three-fold lower than native GLP-1 owing to albumin binding
Albumin (non-receptor)Reversible binding via C18 diacidDrives the extended half-life; >99 % bound in plasma
Neuraminidase-resistant DPP-4 cleavage siteNot a target — structurally protectedAib8 substitution prevents N-terminal degradation

§2.2Mechanism of action

Semaglutide is a full agonist at the glucagon-like peptide-1 receptor, a class B G protein-coupled receptor signalling principally through Gαs and adenylyl cyclase. In pancreatic beta cells the resulting rise in cyclic AMP potentiates glucose-dependent insulin secretion; in alpha cells it suppresses glucagon release at euglycaemia and above. Peripheral effects include delayed gastric emptying. Central effects, mediated through GLP-1 receptor populations in the area postrema, nucleus tractus solitarius, arcuate nucleus and other hypothalamic sites accessible to circulating peptide, reduce appetite and energy intake; the weight effect is attributed principally to this central action rather than to gastric emptying, which shows partial tachyphylaxis with continued dosing.[1,2]

§2.3Pharmacokinetics

Terminal half-life
≈165 h (approximately 7 days)
Time to maximum concentration
1–3 days after subcutaneous injection
Volume of distribution
≈12.5 L
Plasma protein binding
>99 % (albumin)
Clearance
≈0.05 L/h
Bioavailability
≈89 % absolute bioavailability (subcutaneous)

Proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty-acid side chain. Approximately 3 % of the dose is excreted as intact peptide in urine. Steady state is reached after 4–5 weeks of weekly dosing.

Reconstructed plasma concentration–time profilePlasma concentration plotted against time after dosing, reconstructed from published pharmacokinetic parameters.0.00.51.01.50200400600800Time after first dose (hours)Relative concentrationt max ≈ 555 ht½ ≈ 165 h
Modelled profileSimulated observationsDose administration
Figure 2. Illustrative. Plasma concentration–time profile reconstructed by the Institute from the published half-life and time-to-maximum-concentration parameters using a one-compartment model with first-order absorption. The curve is not digitised from a published figure and its vertical scale is relative. It is published to convey the shape of the profile and the approach to steady state, not to supply a concentration at any time point.

§2.4Interactions

  • Delayed gastric emptying may alter the rate, though generally not the extent, of absorption of concomitant oral medicines
  • Insulin secretagogues and insulin require dose reduction to limit hypoglycaemia
  • No clinically relevant cytochrome P450 interaction has been identified; semaglutide is not a substrate, inducer or inhibitor of the major isoforms

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
  2. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.